EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Review of Suspected Alport Syndrome Patients—A Single-Centre Experience

Paulina Halat-Wolska iD, Elżbieta Ciara iD, Michał Pac, Łukasz Obrycki iD, Dorota Wicher iD, Katarzyna Iwanicka-Pronicka, Ewelina Bielska, Beata Chałupczyńska, Dorota Siestrzykowska, Grażyna Kostrzewa, Piotr Stawiński, Rafał Płoski und 2 weitere

Genes · 2025

DOI: 10.3390/genes16020196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Paulina Halat-Wolska und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, The Children's Memorial Health Institute, 04-730 Warsaw, Poland. Hauptthemen laut MEDLINE: Nephritis, Hereditary, Collagen Type IV, Autoantigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CMHI, MEiN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alport syndrome (AS) is a clinically and genetically heterogeneous glomerulopathy resulting from pathogenic variants in COL4A3, COL4A4, and COL4A5. Genetic diagnosis is increasingly being conducted using next-generation sequencing (NGS).

Methods

Within eight years, we examined a group of 247 Polish individuals and found in total 138 unrelated probands suspected with AS based on clinical course, laboratory findings, and/or family history, as well as the total of 109 family members. We applied a targeted NGS panel to identify the genetic spectrum of AS. Known and novel variants were revealed, and detailed evaluation was performed according to ACMG/AMP guidelines to classify them as pathogenic/likely pathogenic/VUS changes. Identified genotypes were compared with clinical manifestations: hematuria, proteinuria, chronic kidney disease, sensorineural hearing impairment, ocular abnormalities, and hypertension.

Results

The molecular background was established in 109/138 probands. Overall, 79 different COL4A3-COL4A5 changes (56 known and 23 novel) were revealed. About 97% were SNVs, and only two COL4A5 CNVs were identified. In total, 11 recurrent COL4A3-COL4A5 variants were observed, including the most frequent COL4A5:p.Gly624Asp, accounting for 31% of X-linked AS.

Conclusions

The use of NGS panel has shown considerable promise in the field of AS, increasing diagnostic rate to 79% and reducing time to diagnosis. The phenotype-driven gene panel, specific for genetic diseases in the pediatric population, is an affordable alternative to WGS and WES, offering comparable diagnostic efficacy and supporting its implementation as a first-line genetic test in rare diseases, including AS. Based on the obtained genotype–phenotype correlation, we assessed that NGS allows us to avoid invasive renal biopsy in AS diagnosis. It provides AS confirmation/exclusion, atypical AS identification, symptomatic/asymptomatic monoallelic COL4A3-COL4A5 carrier (especially COL4A5 females) determination, and inheritance pattern establishment. AS diagnosis confirmation enables clinical course prediction and is crucial for the early introduction of renoprotective treatment with renin–angiotensin–aldosterone system blockade, aimed at slowing the disease progression and estimating the risk in family members, which is important for genetic counselling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephritis, HereditaryCollagen Type IVAutoantigensHumansMaleFemaleChildAdultHigh-Throughput Nucleotide SequencingAdolescentChild, PreschoolMiddle AgedMutationYoung AdultGenetic TestingPedigree

Stichwörter der Autor:innen

Alport syndromeCOL4A3COL4A4COL4A5genetic testingnext-generation sequencingnovel molecular variants

Substanzen

Collagen Type IVCOL4A5 protein, humanAutoantigenstype IV collagen alpha3 chainCOL4A4 protein, human

Autor:innen und Institutionen

  • Department of Medical Genetics, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
  • Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
  • Department of Medical Genetics, Warsaw Medical University, 02-106 Warsaw, Poland.

ORCID-Profile: Paulina Halat-Wolska, Elżbieta Ciara, Łukasz Obrycki, Dorota Wicher, Mieczysław Litwin, Krystyna Chrzanowska

Förderung

  • CMHI
  • MEiN

Zitieren

APA

Halat-Wolska, P., Ciara, E., Pac, M., Obrycki, Ł., Wicher, D., Iwanicka-Pronicka, K., Bielska, E., Chałupczyńska, B., Siestrzykowska, D., Kostrzewa, G., Stawiński, P., Płoski, R., Litwin, M., & Chrzanowska, K. (2025). Molecular Review of Suspected Alport Syndrome Patients—A Single-Centre Experience. Genes. https://doi.org/10.3390/genes16020196

Vancouver

Halat-Wolska P, Ciara E, Pac M, Obrycki Ł, Wicher D, Iwanicka-Pronicka K, et al. Molecular Review of Suspected Alport Syndrome Patients—A Single-Centre Experience. Genes. 2025. doi:10.3390/genes16020196

BibTeX
@article{HalatWolska2025,
  author = {Halat-Wolska, Paulina and Ciara, Elżbieta and Pac, Michał and Obrycki, Łukasz and Wicher, Dorota and Iwanicka-Pronicka, Katarzyna and Bielska, Ewelina and Chałupczyńska, Beata and Siestrzykowska, Dorota and Kostrzewa, Grażyna and Stawiński, Piotr and Płoski, Rafał and Litwin, Mieczysław and Chrzanowska, Krystyna},
  title = {Molecular Review of Suspected Alport Syndrome Patients—A Single-Centre Experience},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16020196}
}
Kostenlos starten →